Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Retained Earnings (2020 - 2026)

MoonLake Immunotherapeutics' Retained Earnings history spans 7 years, with the latest figure at $322000.0 for Q1 2026.

  • Quarterly Retained Earnings rose 100.12% to $322000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $322000.0 through Mar 2026, up 100.12% year-over-year, with the annual reading at $604000.0 for FY2025, 87.91% down from the prior year.
  • Retained Earnings came in at $322000.0 for Q1 2026, down from $604000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $5.0 million in Q4 2024 to a low of -$275.5 million in Q1 2025.
  • The 5-year median for Retained Earnings is $322000.0 (2026), against an average of -$40.5 million.
  • The largest YoY upside for Retained Earnings was 1072.2% in 2023 against a maximum downside of 74727.66% in 2023.
  • MoonLake Immunotherapeutics' Retained Earnings stood at $350946.0 in 2022, then surged by 571.79% to $2.4 million in 2023, then soared by 111.95% to $5.0 million in 2024, then plummeted by 87.91% to $604000.0 in 2025, then tumbled by 46.69% to $322000.0 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Retained Earnings are $322000.0 (Q1 2026), $604000.0 (Q4 2025), and $278000.0 (Q3 2025).